CN110167939A - 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 - Google Patents

吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN110167939A
CN110167939A CN201880006265.9A CN201880006265A CN110167939A CN 110167939 A CN110167939 A CN 110167939A CN 201880006265 A CN201880006265 A CN 201880006265A CN 110167939 A CN110167939 A CN 110167939A
Authority
CN
China
Prior art keywords
alkyl
naphthenic base
halogenated
alkoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880006265.9A
Other languages
English (en)
Other versions
CN110167939B (zh
Inventor
苏熠东
古鹏
陈晓坡
刘磊
包如迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN110167939A publication Critical patent/CN110167939A/zh
Application granted granted Critical
Publication of CN110167939B publication Critical patent/CN110167939B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

本发明公开了吡咯并[2,3‑c]吡啶类衍生物、其制备方法及其在医药上的应用。特别地，本发明公开了通式(I)所示的吡咯并[2,3‑c]吡啶类衍生物、其制备方法及含有该衍生物的药物组合物，及其作为BRD4抑制剂在治疗癌症、炎症、慢性肝病、糖尿病、心血管疾病和AIDS等相关疾病的用途，其中通式(I)中的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN201880006265.9A 2017-01-11 2018-01-11 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 Active CN110167939B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201710021323 2017-01-11
CN2017100213232 2017-01-11
CN2017105559612 2017-07-10
CN201710555961 2017-07-10
CN201710980571X 2017-10-19
CN201710980571 2017-10-19
PCT/CN2018/072204 WO2018130174A1 (zh) 2017-01-11 2018-01-11 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN110167939A true CN110167939A (zh) 2019-08-23
CN110167939B CN110167939B (zh) 2021-12-31

Family

ID=62839289

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880006265.9A Active CN110167939B (zh) 2017-01-11 2018-01-11 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用

Country Status (3)

Country Link
CN (1) CN110167939B (zh)
TW (1) TW201825490A (zh)
WO (1) WO2018130174A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113173877A (zh) * 2020-10-30 2021-07-27 江西师范大学 吲哚乙酰基亚氨基砜系列化合物及其制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3442972T3 (pl) 2016-04-15 2020-07-27 Abbvie Inc. Inhibitory bromodomeny
CN110577526B (zh) * 2018-06-07 2023-10-27 上海翰森生物医药科技有限公司 溴域结构蛋白抑制剂的盐及其制备方法和应用
CA3106733A1 (en) * 2018-07-25 2020-01-30 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Sulfoximine compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof
CN110776508B (zh) * 2018-07-27 2021-07-16 海创药业股份有限公司 一种brd4抑制剂及其制备方法和用途
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
MX2022000050A (es) 2019-07-02 2022-05-24 Nuvation Bio Inc Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
JP2023510610A (ja) * 2020-01-19 2023-03-14 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド ブロモドメインタンパク質阻害剤の結晶形、塩形態及びその製造方法
US20230174545A1 (en) * 2020-04-29 2023-06-08 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors
GB202016977D0 (en) 2020-10-26 2020-12-09 In4Derm Ltd Compounds
AU2021403544A1 (en) 2020-12-14 2023-06-29 Basf Se Sulfoximine pesticides
CA3224302A1 (en) 2021-06-29 2023-01-05 Tay Therapeutics Limited Pyrrolopyridone derivatives useful in the treatment of cancer
CN114133367B (zh) * 2021-10-18 2023-03-21 大连理工常熟研究院有限公司 一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2014125408A2 (en) * 2013-02-12 2014-08-21 Aurigene Discovery Technologies Limited Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
CN105026403B (zh) * 2013-03-12 2018-05-18 艾伯维公司 四环布罗莫结构域抑制剂
RU2016102647A (ru) * 2013-06-28 2017-08-01 Эббви Инк. Ингибиторы бромодомена
EP3043784B9 (en) * 2013-09-09 2019-11-20 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
WO2015081280A1 (en) * 2013-11-26 2015-06-04 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution
NZ763740A (en) * 2014-04-23 2023-06-30 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
MA40943A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
WO2016145032A1 (en) * 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016145045A1 (en) * 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
WO2016168510A1 (en) * 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113173877A (zh) * 2020-10-30 2021-07-27 江西师范大学 吲哚乙酰基亚氨基砜系列化合物及其制备方法
CN113173877B (zh) * 2020-10-30 2023-10-27 江西师范大学 吲哚乙酰基亚氨基砜系列化合物及其制备方法

Also Published As

Publication number Publication date
TW201825490A (zh) 2018-07-16
CN110167939B (zh) 2021-12-31
WO2018130174A1 (zh) 2018-07-19

Similar Documents

Publication Publication Date Title
CN110167939A (zh) 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
CA3029857C (en) Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
CN111377917B (zh) 杂环类化合物、中间体、其制备方法及应用
CN105828820B (zh) 布罗莫结构域抑制剂
KR102057877B1 (ko) 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도
CN106715440B (zh) 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
CN108929263B (zh) 芳酰胺类Kv2.1抑制剂及其制备方法、药物组合物和用途
CN110078741B (zh) 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
CN107428742A (zh) 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN111094233A (zh) 化合物、组合物及方法
CN108495850A (zh) 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
CN113286794A (zh) Kras突变蛋白抑制剂
CN107235883B (zh) 二芳基-β-内酰胺类化合物及其制备方法和在制药中的用途
CN111315380A (zh) 凋亡信号调节激酶抑制剂及其用途
TW201722929A (zh) 苯并哌啶類衍生物、其製備方法及其在醫藥上的應用
CN107001271A (zh) 羟基脒类衍生物、其制备方法及其在医药上的应用
WO2022268230A1 (zh) 作为kif18a抑制剂的化合物
JP7307796B2 (ja) アンドロゲン受容体分解活性を有する新規の置換キノリン－８－カルボニトリル誘導体およびその使用
WO2022194066A1 (zh) Kras g12d抑制剂及其在医药上的应用
CN110198941A (zh) 吡咯并吡啶类n-氧化衍生物及其制备方法和应用
JP7152078B2 (ja) ホウ酸塩ベースの薬物およびその使用
CN115785154A (zh) 杂芳环化合物及其医药用途
CN113698390B (zh) 用作ret激酶抑制剂的化合物及其应用
CN110088098A (zh) 喹唑啉酮类parp-1抑制剂及其制备方法、药物组合物和用途
WO2017167183A1 (zh) 二芳基-β-内酰胺类化合物及其制备方法和在制药中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40006870

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant